Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

Fig. 1

Treatment outcomes with pembrolizumab with or without chemotherapy for pulmonary large-cell carcinoma (LCC; n = 42) and large-cell neuroendocrine carcinoma (LCNEC; n = 18). A Waterfall plot of the maximum percent change in tumor size of target lesions from baseline. The patients were grouped according to histological subtypes. Clinical details of each patient were annotated and represented by various colors. Red dashed line denotes the threshold of 20% increase in tumor size relative to baseline and evaluated as progressive disease (PD). Blue dashed line denotes the threshold of 30% reduction in tumor size relative to baseline and evaluated as partial response (PR); B Swimmer plot showing the time on treatment, which is calculated starting on the day treatment is initiated until disease is evaluated as progressive disease (PD). The patients were grouped according to treatment setting. The histological subtype and best response were indicated by colors. Diamond shapes indicate the patients who are still receiving treatment at data cut-off. The median follow-up of the cohort is 12 months

Back to article page